CD137+ and regulatory T cells as independent prognostic factors of survival in advanced non-oncogene addicted NSCLC patients treated with immunotherapy as first-line
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
CD137+ and regulatory T cells as independent prognostic factors of survival in advanced non-oncogene addicted NSCLC patients treated with immunotherapy as first-line ; volume:22 ; number:1 ; day:3 ; month:4 ; year:2024 ; pages:1-16 ; date:12.2024
Journal of translational medicine ; 22, Heft 1 (3.4.2024), 1-16, 12.2024
- Creator
-
Gelibter, Alain
Asquino, Angela
Strigari, Lidia
Zizzari, Ilaria Grazia
Tuosto, Lucrezia
Scirocchi, Fabio
Pace, Angelica
Siringo, Marco
Tramontano, Elisa
Bianchini, Serena
Bellati, Filippo
Botticelli, Andrea
Paoli, Donatella
Santini, Daniele
Nuti, Marianna
Rughetti, Aurelia
Napoletano, Chiara
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12967-024-05142-6
- URN
-
urn:nbn:de:101:1-2406190941109.256089408127
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:57 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Gelibter, Alain
- Asquino, Angela
- Strigari, Lidia
- Zizzari, Ilaria Grazia
- Tuosto, Lucrezia
- Scirocchi, Fabio
- Pace, Angelica
- Siringo, Marco
- Tramontano, Elisa
- Bianchini, Serena
- Bellati, Filippo
- Botticelli, Andrea
- Paoli, Donatella
- Santini, Daniele
- Nuti, Marianna
- Rughetti, Aurelia
- Napoletano, Chiara
- SpringerLink (Online service)
Other Objects (12)
circ_0005962 functions as an oncogene to aggravate NSCLC progression
Non-tumor-related prognostic factors for immunotherapy–chemotherapy or immunotherapy alone as first-line in advanced non-small cell lung cancer (NSCLC)
Correction to: Osimertinib as first-line therapy in advanced NSCLC: a profile of its use
Role of antiangiogenic agents in first-line treatment for advanced NSCLC in the era of immunotherapy
TdIF1: a putative oncogene in NSCLC tumor progression
LncRNA OGFRP1 acts as an oncogene in NSCLC via miR-4640-5p/eIF5A axis
Multi-institutional prognostic modeling of survival outcomes in NSCLC patients treated with first-line immunotherapy using radiomics
ZBTB7A functioned as an oncogene in colorectal cancer
Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study
Podcast on Lorlatinib as a First-Line Treatment Option for Patients with ALK-Positive Metastatic NSCLC with Brain Metastasis
Tongue as a first-line immune organ?
Impact of NSCLC metabolic remodeling on immunotherapy effectiveness
circ_0005962 functions as an oncogene to aggravate NSCLC progression
Non-tumor-related prognostic factors for immunotherapy–chemotherapy or immunotherapy alone as first-line in advanced non-small cell lung cancer (NSCLC)
Correction to: Osimertinib as first-line therapy in advanced NSCLC: a profile of its use
Role of antiangiogenic agents in first-line treatment for advanced NSCLC in the era of immunotherapy
TdIF1: a putative oncogene in NSCLC tumor progression
LncRNA OGFRP1 acts as an oncogene in NSCLC via miR-4640-5p/eIF5A axis
Multi-institutional prognostic modeling of survival outcomes in NSCLC patients treated with first-line immunotherapy using radiomics
ZBTB7A functioned as an oncogene in colorectal cancer
Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study
Podcast on Lorlatinib as a First-Line Treatment Option for Patients with ALK-Positive Metastatic NSCLC with Brain Metastasis
Tongue as a first-line immune organ?
Impact of NSCLC metabolic remodeling on immunotherapy effectiveness
circ_0005962 functions as an oncogene to aggravate NSCLC progression
Non-tumor-related prognostic factors for immunotherapy–chemotherapy or immunotherapy alone as first-line in advanced non-small cell lung cancer (NSCLC)
Correction to: Osimertinib as first-line therapy in advanced NSCLC: a profile of its use
Role of antiangiogenic agents in first-line treatment for advanced NSCLC in the era of immunotherapy
TdIF1: a putative oncogene in NSCLC tumor progression
LncRNA OGFRP1 acts as an oncogene in NSCLC via miR-4640-5p/eIF5A axis
Multi-institutional prognostic modeling of survival outcomes in NSCLC patients treated with first-line immunotherapy using radiomics
ZBTB7A functioned as an oncogene in colorectal cancer
Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study
Podcast on Lorlatinib as a First-Line Treatment Option for Patients with ALK-Positive Metastatic NSCLC with Brain Metastasis
Tongue as a first-line immune organ?